
A study investigated the impact of denosumab on type 2 diabetes (T2D) incidence and long-term health outcomes in patients previously without T2D or cancer. The study included 331,375 patients who compared denosumab (n = 45,854) to bisphosphonates (n = 285,521). Denosumab use was associated with a 17% lower risk of incident T2D over five years and significant reductions in all-cause mortality and foot ulceration. Meta-analysis of prior studies confirmed a consistent risk reduction in T2D incidence with denosumab. These findings suggest potential benefits of denosumab beyond osteoporosis treatment, influencing future guidelines for managing osteoporosis in patients at risk of T2D.
Like
Save
Share